Health systems across the country are making it easier for primary care clinicians to order genetic tests for patients who ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...

In a recent study, Mass General Brigham researchers demonstrated that through low-cost genetic samples that can be obtained ...

AI-driven genomics startups leverage technology to analyze genetic data, predict predispositions, and offer personalized ...

The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.

After a genetic test, Alex Swanson learned he has hereditary hemochromatosis, a condition causing iron overload that can lead ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Molecular profiling and genetic testing have revolutionised lung cancer treatment, says a doctor. They have enabled targeted therapies that are more effective and tolerable than traditional ...

Rates of genetic testing for autism and intellectual and development disorders were associated with race, gender, and insurance company.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Significant racial disparities persisted in genetic testing for inborn errors of immunity despite the removal of financial ...